MitoPRO X
6 wavelengths, touchscreen, app control. Medical-grade performance.
from $449.00
MitoADAPT 4.0
8 wavelengths, 11 modes, patent-pending TruDUAL™ chip technology.
from $549.00
MitoPRO+
4 wavelengths, exceptional power, unbeatable value.
from $369.00
Mito Red Original 2.0
660nm + 850nm. ETL certified. Great value starting point.
from $249.00
MitoAURA Complete System
MitoAURA 3-Step System is the first skincare protocol engineered to work with your red and near-infrared light therapy sessions, not just alongside them.
from $93.00
MitoAURA Serum
Light-responsive. Firms, brightens, and amplifies every session.
from $40.00
MitoGLOW Mask
FDA-cleared LED mask. 1,064 LEDs, 4 wavelengths, 5 modes.
from $499.00
MitoAURA™ Gentle Cleanser
Gently cleanses without stripping skin's natural moisture.
from $25.00
MitoAURA™ Prime Pre-LED Serum
Helps prepare and condition skin for red light therapy.
from $39.00
MitoAURA™ Seal Post LED Moisturizer
Helps lock in moisture and support long-lasting hydration.
from $39.00
MitoPRO Mobile
5 wavelengths, pulse mode, UL-listed battery. Pro light anywhere.
from $349.00
MitoQUAD Belt
Hands-free wearable belt. UL medical grade, 4 wavelengths.
from $349.00
MitoPOD
Full-body pod. IEC 60601 certified, 6,960 LEDs total.
from $1,699.00
MitoBOOST
Intranasal device. Red, blue & NIR for sinus, immune & brain.
from $199.00
What is Red Light Therapy
The science behind PBM — how red and near-infrared light works at the cellular level.
The Mito Red Difference
Why our devices outperform — specs, certifications, and build quality explained.
In the Press
Media coverage, expert reviews, and editorial features.
FAQ
Common questions about devices, protocols, safety, and shipping.
Take the Quiz
Four quick questions to find the right panel for your goals.
Research & Evidence
Browse the clinical studies and data behind photobiomodulation therapy.
Community
Meet the Mito Red community — real people, real results.
Four quick questions. One recommendation.
By treatment area
Formulated to work with light — not just alongside it. Young Goose collab. EWG Green. Made in USA.
BEST VALUE
COMING SOON
STEP 1
STEP 2
STEP 3
About the research on this page. The studies cited here investigate photobiomodulation (PBM) as a therapeutic modality and the specific wavelengths used in PBM research — not Mito Red Light devices. The wavelengths in our panels were chosen because the peer-reviewed PBM literature supports them. Evidence levels and study counts reflect the broader research base, not studies of our products. See the full methodology note at the bottom of this page.
Controlled trials show that red and near-infrared light can improve signs of skin aging. In a trial of 113 people, red and near-infrared light improved skin complexion, roughness and ultrasound-measured collagen density compared with untreated controls (Wunsch 2014). A 2023 randomized trial of 137 people found about a 30% reduction in wrinkle volume around the eyes after 4 weeks of red (660 nm) or amber (590 nm) light, although hydration and elasticity did not change (Mota 2023). A 2025 sham-controlled trial found shorter glabellar and eye-area wrinkles and higher satisfaction, and more sessions did not improve results beyond two a week (Bragato 2025).
Beyond aging, preventive light therapy reduced severe radiation dermatitis in cancer patients in a 2023 meta-analysis (Gobbo 2023). A 2023 meta-analysis of 31 studies found benefits of LEDs across several skin conditions (Ngoc 2023). For acne, a 2021 meta-analysis of 13 trials found red light no better than conventional treatments (Wu 2021). A 2023 systematic review found no clinical evidence linking light therapy for skin rejuvenation to new or recurrent cancer (Glass 2023).
Based on 536 indexed studies in this category, 269 of them in people. These studies test photobiomodulation in general, not Mito Red Light devices.
Number of studies in our database for each condition. Direction and certainty are shown only where a meta-analysis or systematic review reports them; otherwise the row says "not graded".
| Condition | Human randomized trials | All human studies | Direction of results | Certainty |
|---|---|---|---|---|
| Acne vulgaris | 16 | 42 | Red light not better than conventional treatment Wu 2021 (PMID 34363730) |
Not graded; authors advise caution |
| Skin rejuvenation | 15 | 39 | Fewer wrinkles and more collagen in controlled trials Mota 2023 (PMID 36780572); Wunsch 2014 (PMID 24286286) |
Not graded by authors |
| Herpes zoster | 9 | 25 | Not graded | Not graded |
| Body contouring | 10 | 18 | Not graded | Not graded |
| Scars (clinical) | 10 | 18 | Not graded | Not graded |
| Herpes labialis | 11 | 18 | Not graded | Not graded |
| Radiation dermatitis | 9 | 15 | Less severe dermatitis with preventive use Gobbo 2023 (PMID 36952036) |
Not graded by authors |
| Laser skin resurfacing wounds / erythema | 8 | 9 | Not graded | Not graded |
| Dermatology | 1 | 8 | Not graded | Not graded |
| Onychomycosis | 4 | 7 | Not graded | Not graded |
| Melasma | 2 | 5 | Not graded | Not graded |
| Rosacea | 1 | 5 | Not graded | Not graded |
| Psoriasis | 2 | 4 | Not graded | Not graded |
| Vitiligo | 1 | 4 | Not graded | Not graded |
| Atopic dermatitis | 1 | 3 | Not graded | Not graded |
The strongest human evidence: systematic reviews and meta-analyses first, then the newest randomized trials. Each card comes straight from our study database and links to the paper.
Ngoc et al., Photodermatol Photoimmunol Photomed, 2023. PMID 36310510
Bragato et al., Lasers Med Sci, 2025. PMID 40167796
Mota et al., Photobiomodul Photomed Laser Surg, 2023. PMID 36780572
Wunsch & Matuschka et al., Photomed Laser Surg, 2014. PMID 24286286
Wu et al., J Cosmet Dermatol, 2021. PMID 34363730
Gobbo et al., Support Care Cancer, 2023. PMID 36952036
Glass GE et al., Aesthet Surg J, 2023. PMID 36722207
Not every trial is positive. "No effect" means the main outcome did not differ from sham or control. "Mixed" means some outcomes improved but the outcome named here did not differ.
The 25 most recent human studies in our database for this category.
Wavelengths reported in our database for the 118 human randomized trials in this category (69 wavelength entries; many database records lack a wavelength, and some trials report more than one). This describes the research; it is not a dosing recommendation.
| Wavelength band | Times used in trials |
|---|---|
| Red (600-699 nm) | 29 |
| Blue/green (400-599 nm) | 23 |
| Near-infrared (800-899 nm) | 15 |
| Near-infrared (900-1200 nm) | 2 |
Most common wavelengths: 630-639 nm, 590-599 nm, 800-809 nm, 850-859 nm, 660-669 nm.
Controlled trials say yes, modestly. Red and amber light reduced wrinkle volume around the eyes by about 30% in a 137-person randomized trial (Mota 2023), and red and near-infrared light increased collagen density in a 113-person controlled trial (Wunsch 2014).
In a 2025 sham-controlled trial, the number of sessions did not change results, and the authors concluded two sessions a week seem sufficient (Bragato 2025).
The evidence is mixed. A 2023 meta-analysis found red and blue LEDs reduced acne lesions (Ngoc 2023), but a 2021 meta-analysis of 13 trials found red light no better than conventional treatments (Wu 2021).
A 2023 systematic review found no clinical trial data linking light therapy for skin rejuvenation to new or recurrent cancer, and no evidence that cancer survivors should avoid it (Glass 2023).
All 536 studies in this category from our study database, built on the PBM Research Database by Vladimir Heiskanen.
Search every study across all categories: Open the Full Evidence Explorer →
The published research indexed and referenced on this page studies photobiomodulation (PBM) as a therapeutic modality and the specific wavelengths used in those studies — not Mito Red Light devices specifically. The wavelengths used across our panels were chosen because the peer-reviewed PBM literature supports them: this is where published evidence is deepest, where dosing parameters have been characterized in human studies, and where clinical guidelines (such as WALT for inflammation and pain) exist. Mito Red Light has not funded or conducted registered clinical trials on our specific devices, and the study counts referenced here reflect the broader PBM research base — not studies of our products.
Where review authors graded certainty (for example with GRADE), we report their grade; other ratings are Mito’s summary. Study counts reflect peer-reviewed photobiomodulation research drawn from major scientific literature databases, peer-reviewed journals, and other published research repositories. PBM response varies meaningfully by person, tissue, condition, dose, wavelength, and session timing; outcomes reported in the published literature may not be replicable for every user. Mito Red Light devices are not intended to diagnose, treat, cure, or prevent any disease. If you have a medical condition or are under a physician’s care, please consult your healthcare provider before beginning any photobiomodulation regimen.
